Salvador JAR - Search Results

1

Bioactive Bismuth Compounds: Is Their Toxicity a Barrier to Therapeutic Use?

Gonçalves Â, Matias M, Salvador JAR, Silvestre S. Gonçalves Â, et al. Among authors: salvador jar. Int J Mol Sci. 2024 Jan 27;25(3):1600. doi: 10.3390/ijms25031600. Int J Mol Sci. 2024. PMID: 38338879 Free PMC article. Review.

2

Recent advances in oridonin derivatives with anticancer activity.

Sobral PJM, Vicente ATS, Salvador JAR. Sobral PJM, et al. Among authors: salvador jar. Front Chem. 2023 Feb 9;11:1066280. doi: 10.3389/fchem.2023.1066280. eCollection 2023. Front Chem. 2023. PMID: 36846854 Free PMC article. Review.

3

Therapeutic potential of glutaminyl cyclases: Current status and emerging trends.

Coimbra JRM, Moreira PI, Santos AE, Salvador JAR. Coimbra JRM, et al. Among authors: salvador jar. Drug Discov Today. 2023 Oct;28(10):103644. doi: 10.1016/j.drudis.2023.103644. Epub 2023 May 26. Drug Discov Today. 2023. PMID: 37244566 Free article. Review.

4

Artificial intelligence for prediction of biological activities and generation of molecular hits using stereochemical information.

Pereira TO, Abbasi M, Oliveira RI, Guedes RA, Salvador JAR, Arrais JP. Pereira TO, et al. Among authors: salvador jar. J Comput Aided Mol Des. 2023 Dec;37(12):791-806. doi: 10.1007/s10822-023-00539-9. Epub 2023 Oct 17. J Comput Aided Mol Des. 2023. PMID: 37847342 Free PMC article.

5

Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome.

Fernandes PMP, Guedes RA, Victor BL, Salvador JAR, Guedes RC. Fernandes PMP, et al. Among authors: salvador jar. Front Chem. 2024 Jan 8;11:1322628. doi: 10.3389/fchem.2023.1322628. eCollection 2023. Front Chem. 2024. PMID: 38260042 Free PMC article.

6

Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment.

Carreira LD, Oliveira RI, Moreira VM, Salvador JAR. Carreira LD, et al. Among authors: salvador jar. Expert Opin Ther Targets. 2023 Jul-Dec;27(11):1043-1058. doi: 10.1080/14728222.2023.2266571. Epub 2023 Dec 7. Expert Opin Ther Targets. 2023. PMID: 37789645 Review.

7

New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies.

Guedes RA, Grilo JH, Carvalho AN, Fernandes PMP, Ressurreição AS, Brito V, Santos AO, Silvestre S, Gallerani E, Gama MJ, Gavioli R, Salvador JAR, Guedes RC. Guedes RA, et al. Among authors: salvador jar. Pharmaceuticals (Basel). 2023 Aug 2;16(8):1096. doi: 10.3390/ph16081096. Pharmaceuticals (Basel). 2023. PMID: 37631011 Free PMC article.

8

Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review.

Vicente ATS, Salvador JAR. Vicente ATS, et al. Among authors: salvador jar. Expert Opin Ther Pat. 2023 Jan-Jun;33(6):397-420. doi: 10.1080/13543776.2023.2240025. Epub 2023 Jul 26. Expert Opin Ther Pat. 2023. PMID: 37494069 Review.

9

Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents.

Gonçalves BMF, Mendes VIS, Silvestre SM, Salvador JAR. Gonçalves BMF, et al. Among authors: salvador jar. RSC Med Chem. 2022 Dec 19;14(2):313-331. doi: 10.1039/d2md00275b. eCollection 2023 Feb 22. RSC Med Chem. 2022. PMID: 36846362 Free PMC article.

10

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.

Vicente ATS, Salvador JAR. Vicente ATS, et al. Among authors: salvador jar. Int J Mol Sci. 2022 Sep 21;23(19):11068. doi: 10.3390/ijms231911068. Int J Mol Sci. 2022. PMID: 36232374 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page